ECI2抗体—艾普蒂 新品

The ECI2 (Enoyl-CoA Delta Isomerase 2) antibody targets a mitochondrial enzyme crucial in fatty acid β-oxidation. ECI2. also known as DCI or PECI, catalyzes the isomerization of 3-trans-enoyl-CoA to 2-trans-enoyl-CoA intermediates, facilitating the breakdown of unsaturated fatty acids for energy production. This enzyme plays a vital role in lipid metabolism, particularly in tissues with high energy demands, such as liver, heart, and skeletal muscle. Dysregulation of ECI2 has been linked to metabolic disorders, including insulin resistance and type 2 diabetes, as well as certain cancers due to altered lipid utilization in tumor microenvironments. Antibodies against ECI2 are essential tools for studying its expression, localization, and function in metabolic pathways. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding research into metabolic diseases and cancer biology. Recent studies also explore ECI2's potential as a biomarker or therapeutic target, emphasizing the antibody's diagnostic and research relevance. Commercial ECI2 antibodies are typically validated for specificity across human and model organism samples, supporting both basic and translational investigations.